Could a popular Weight-Loss drug also help paralyzed patients manage diabetes?
NCT ID NCT06706284
Summary
This study is testing if the diabetes and weight-loss drug semaglutide (Ozempic) works well for people who have both a spinal cord injury and type 2 diabetes. About 50 participants will receive either the real drug or a placebo injection once a week for 24 weeks. Researchers will measure changes in blood sugar control, body weight, and body fat to see if the drug is effective and safe for this specific group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Health - Texas Diabetic Institute
RECRUITINGSan Antonio, Texas, 78207, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
University of Texas Health Science Center at San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.